drugset / Trial / NCT01561053
A Study to Evaluate Albumin and Immunoglobulin in Alzheimer's Disease
RandomizedParallel-groupTriple-blindTreatment
Summary
The purpose of this study is to evaluate the changes in the cognitive, functional, behavioral and global domains based on the different applicable psychometric batteries and scales.
Timeline
- Start
- 2012-04-19
- Primary completion
- 2018-03-06
- Completion
- 2018-03-06
Publications
- Podger L, Stewart WF, Serrano D, Lipton RB, Gomez-Ulloa D, Ayasse ND, Barnes FB, Davis EA, Runken MC. Application of a Novel Endpoint Staging Framework: Proof of Concept in the AMBAR Study. J Alzheimers Dis. 2024;98(3):1079-1094. doi: 10.3233/JAD-231197.
- Cuberas-Borros G, Roca I, Castell-Conesa J, Nunez L, Boada M, Lopez OL, Grifols C, Barcelo M, Pareto D, Paez A. Neuroimaging analyses from a randomized, controlled study to evaluate plasma exchange with albumin replacement in mild-to-moderate Alzheimer's disease: additional results from the AMBAR study. Eur J Nucl Med Mol Imaging. 2022 Nov;49(13):4589-4600. doi: 10.1007/s00259-022-05915-5. Epub 2022 Jul 22.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Albumin | Protein / enzyme biologic | 5 % | — |
| Subject | Albumin 20% | Protein / enzyme biologic | 20 % | — |
| Subject | Immune Globulin Intravenous (Human) | Protein / enzyme biologic | 5 % | Intravenous |